A Dose of Optimism, as the Pandemic Rages On
NY Times
OCTOBER 12, 2020
The months ahead will be difficult. But the medical cavalry is coming, and the rest of us know what we need to do.
Sat.Oct 10, 2020 - Fri.Oct 16, 2020
145 
Boehringer, Yale trial digital tech in heart failure
pharmaphorum
OCTOBER 16, 2020
Patients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a new study aims to see if digital health technologies can improve their prospects. The trial – run by Boehringer Ingelheim and Yale University – will test a smart bathroom scale device that has cardiac monitoring built in, as well as an app to help patients improve their diet and lose weight and a digital assistant designed to motivate them to actively manage their health.
Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
COVID-19: Challenges, Innovation, and What’s Ahead in 2021
Pharma Marketing Network
OCTOBER 13, 2020
Below is a Q&A with Mark Bard, Co-Founder of The DHC Group, who offers his insights on the challenges COVID-19 has brought to pharma, as well as what innovation is taking place due to this full shift to digital and what lies ahead in the future. What is the most challenging aspect of COVID-19 for the industry? Mark Bard: I think the most challenging aspect of the current situation is the inability of anyone – patient, physician, payor, or pharma – to truly predict how long it will take for v
CPhI: Dramatic changes ahead for the generics market
Outsourcing Pharma
OCTOBER 12, 2020
Technology impacting generic drugs include artificial intelligence, telemedicine, fraud-preventing digital solutions and more, according to a report.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial
NY Times
OCTOBER 15, 2020
An antiviral widely used to treat hospitalized patients did not lower the mortality rate in a multinational trial.
Innovation boosts R&D outlook despite COVID difficulties – report
pharmaphorum
OCTOBER 13, 2020
Ayming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably promising” despite strong headwinds caused by COVID-19. The report reveals that R&D departments are being empowered by the creation of ‘innovation ecosystems’, new funding methods, and the deployment of technology.
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
More Trending
First COVID-19 patient treated in Noxopharm study
Outsourcing Pharma
OCTOBER 13, 2020
The clinical-stage drug development company has kicked off testing the experimental anticancer drug Veyonda on severe patients in a Phase I trial.
AZ’s long-acting COVID-19 antibody moves into phase III
Pharma Times
OCTOBER 12, 2020
Two trials will involve over 6,000 participants at sites in and outside the US
Coronavirus re-infection case confirmed in the US
pharmaphorum
OCTOBER 14, 2020
There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US. . It is the fifth confirmed reinfection worldwide after at least four other cases were confirmed in Belgium, the Netherlands, Hong Kong and Ecuador. The latest case was recorded in the Lancet Infectious Diseases journal and involved a 25 year-old man with no known immune disorders or underlying conditions.
The Race for a Super-Antibody Against the Coronavirus
NY Times
OCTOBER 12, 2020
A network of scientists is chasing the pandemic’s holy grail: an antibody that protects against not just the virus, but also related pathogens that may threaten humans.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
New patent for Astrazeneca Ab drug BYDUREON PEN
Drug Patent Watch
OCTOBER 13, 2020
Annual Drug Patent Expirations for BYDUREON+PEN Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-nine…. The post New patent for Astrazeneca Ab drug BYDUREON PEN appeared first on DrugPatentWatch - Make Better Decisions.
BMS’ Zeposia hits the mark in ulcerative colitis
Pharma Times
OCTOBER 12, 2020
Oral S1P receptor modulator hit both primary endpoints in a phase III trial
New CEO Mortazavi takes UK biotech e-therapeutics into gene silencing
pharmaphorum
OCTOBER 13, 2020
UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. Since it was founded in 2001 the company has become one of the country’s best known biotechs thanks to its approach to designing drugs based around network biology. e-therapeutics aims to design drugs that work across several targets that drive complex diseases and its remit has ch
First, a Vaccine Approval. Then ‘Chaos and Confusion.’
NY Times
OCTOBER 12, 2020
Come spring, Americans may have their choice of several so-so coronavirus vaccines — with no way of knowing which one is best.
Current FDA COVID-19 advice and actions
Outsourcing Pharma
OCTOBER 14, 2020
The federal government continues to offer life-sciences professionals advice and resources as they pursue treatments to help fight the COVID-19 virus.
Sanofi’s Dupixent reduces severe asthma attacks in children
Pharma Times
OCTOBER 13, 2020
Biologic therapy hit primary and all key secondary endpoints in phase III
Sanofi preps trials of second COVID-19 shot, as Russia approves another
pharmaphorum
OCTOBER 16, 2020
Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. The French drugmaker’s Sanofi Pasteur vaccines division says it is planning a phase 1/2 trial of the mRNA-based vaccine, called MRT5500, before the end of the year.
Drug May Extend A.L.S. Patients’ Lives by Several Months, Study Finds
NY Times
OCTOBER 16, 2020
The two-drug combination invented by college students is one of many potential therapies being tested for this paralyzing fatal condition.
New patent for Amicus Theraps drug GALAFOLD
Drug Patent Watch
OCTOBER 16, 2020
Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Theraps Us and is included in one NDA. There are twelve patents protecting this drug. This drug…. The post New patent for Amicus Theraps drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.
NICE recommends Novartis’ Mayzent on the heels of SMC approval
Pharma Times
OCTOBER 15, 2020
Drug is licensed for secondary progressive multiple sclerosis with active disease
Rare diseases, repurposing and the role of AI
pharmaphorum
OCTOBER 16, 2020
In the age of artificial intelligence, no trial data should be going to waste. Findacure’s Rick Thompson looks at how these technologies could bring us closer to treatments for underserved rare diseases. The repurposing of drugs is becoming more common, especially in the field of rare diseases. In the past, repurposing has mostly been driven by academics looking for new possibilities in generics.
3 Covid-19 Trials Have Been Paused for Safety. That’s a Good Thing.
NY Times
OCTOBER 14, 2020
Experts were comforted that companies are following safety precautions. They pointed out that pauses in vaccine trials are common, but pauses in treatment trials like Eli Lilly’s are rare.
Novartis shines spotlight on patients living with MS
Outsourcing Pharma
OCTOBER 15, 2020
The pharmaceutical firmâs More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
RPS calls for prevention of counterfeit medicines in UK’s supply chain
Pharma Times
OCTOBER 13, 2020
In a letter to Health Secretary Matt Hancock the RPS called for urgent action
Clear COVID health information essential for return to normal healthcare – report
pharmaphorum
OCTOBER 14, 2020
A lack of clear information on COVID risk is stopping people with long-term conditions accessing the care they need – and could be storing up problems for the future. People living with long-term health conditions have been missing vital tests and monitoring because they fear contracting the novel coronavirus. A survey carried out by the Patient Information Forum (PIF), and supported by Norgine, this summer found that almost one in three respondents had delayed accessing care during the pandemic
New patent for Astrazeneca Ab drug BYDUREON BCISE
Drug Patent Watch
OCTOBER 13, 2020
Annual Drug Patent Expirations for BYDUREON+BCISE Bydureon Bcise is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-one…. The post New patent for Astrazeneca Ab drug BYDUREON BCISE appeared first on DrugPatentWatch - Make Better Decisions.
Clinical technology firm takes a human approach to trials
Outsourcing Pharma
OCTOBER 12, 2020
Study solutions provider H? blends behavioral science, decision economics and technology to better integrate the patient voice into clinical research.
CQC assessment is a ‘wake-up call’ to government, says NHS Confed chief exec
Pharma Times
OCTOBER 16, 2020
Latest reports highlights need for improved access to mental health care
UK biotech sector sets new record with more than £1bn investment in Q3
pharmaphorum
OCTOBER 12, 2020
There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter. Latest figures from the BioIndustry Association representing the UK’s biotech and life sciences sector, showed it raised more than £1 billion in equity finance between June and August, the highest in the sector on record.
New patent expiration for Glaxo Grp drug ADVAIR HFA
Drug Patent Watch
OCTOBER 10, 2020
Annual Drug Patent Expirations for ADVAIR+HFA Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from one supplier. There are…. The post New patent expiration for Glaxo Grp drug ADVAIR HFA appeared first on DrugPatentWatch - Make Better Decisions.
Se han suspendido ensayos clínicos de dos vacunas y un tratamiento para la COVID-19 (y es una buena señal)
NY Times
OCTOBER 15, 2020
Los expertos señalaron que las pausas en los ensayos de vacunas son comunes, aunque detener ensayos de medicamentos, como el de Eli Lilly, es poco frecuente. En ambos casos, dijeron, reconforta la cautela de las compañías.
Bavencio, Imbruvica among latest SMC decisions
Pharma Times
OCTOBER 13, 2020
The committee accepted a number of drugs through the PACE process
Gilead’s COVID-19 drug Veklury falls short in WHO’s global trial
pharmaphorum
OCTOBER 16, 2020
Gilead’s Veklury (remdesivir) has failed to produce an effect on hospital stay and mortality in COVID-19 patients in a large global trial, casting doubt on previous supportive study findings. The results from the World Health Organization’s large Solidarity trial are yet to be peer reviewed but were posted online on a preprint server. Interim findings from Solidarity, which involved more than 11,000 patients in more than 30 countries, contradict those from the manufacturer in a US study.
New patent expiration for Glaxo Grp drug FLOVENT HFA
Drug Patent Watch
OCTOBER 10, 2020
Annual Drug Patent Expirations for FLOVENT+HFA Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from three suppliers. There are…. The post New patent expiration for Glaxo Grp drug FLOVENT HFA appeared first on DrugPatentWatch - Make Better Decisions.
Los anticuerpos son la nueva esperanza contra el COVID-19
NY Times
OCTOBER 16, 2020
Una red de científicos persigue el santo grial de la pandemia: un anticuerpo que no solo protege contra el virus, sino también contra patógenos relacionados que pueden amenazar a los humanos.
Let's personalize your content